ACLX Company Profile and Key Details

Q: Who are the executives of ACLX?

Mr. Narinderjeet Singh M.S.Chief Technical OfficerMs. Michelle Lim GilsonChief Financial OfficerMr. Michael Dombeck M.B.A.Chief Operating OfficerMs. Kate AikenChief People OfficerMr. Rami ElghandourChairman, Chief Executive Officer & PresMr. David Tice Ph.D.Chief Scientific OfficerMs. Maryam Abdul-Kareem J.D., M.S.Gen. CounselMs. Myesha LacyVice President of Investor RelationsDr. Christopher R. Heery M.D.Chief Medical OfficerMr. Neeraj P. TeotiaChief Commercial Officer

NASDAQ : ACLX

Arcellx

$115.07

0.02+0.02%

At Close 4:00 PM

Not Actively Trading

60.9

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Arcellx, Inc. (ACLX) stock surged +0.02%, trading at $115.07 on NASDAQ, up from the previous close of $115.05. The stock opened at $115.03, fluctuating between $115.03 and $115.07 in the recent session.

Stock Snapshot

115.05

Prev. Close

6.73B

Market Cap

115.03

Day Low

-28.272727272727273

P/E Ratio

-4.07

EPS (TTM)

3.56

Cash Flow per Share

115.03

Open

58.51M

Number of Shares

115.07

Day High

74.65%

Free Float in %

9.28

Book Value

13.19M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	115.03	115.07	115.03	115.07	13.19M
Apr 27, 2026	115.04	115.13	114.99	115.07	14.64M
Apr 23, 2026	115.03	115.13	115.01	115.05	1.16M
Apr 22, 2026	115.05	115.06	114.98	115.00	1.04M
Apr 21, 2026	115.07	115.07	114.98	114.98	723.77K
Apr 20, 2026	115.06	115.09	114.99	115.00	726.57K
Apr 17, 2026	115.10	115.11	115.02	115.05	475.56K
Apr 16, 2026	115.02	115.13	115.00	115.10	434.55K
Apr 14, 2026	114.86	114.91	114.86	114.89	543.08K
Apr 13, 2026	114.83	114.91	114.83	114.87	486.09K
Apr 10, 2026	114.80	114.85	114.77	114.83	789.74K
Apr 09, 2026	114.78	114.84	114.77	114.80	362K
Apr 08, 2026	114.83	114.88	114.76	114.79	629.43K
Apr 07, 2026	114.75	114.84	114.72	114.80	914.78K
Apr 06, 2026	114.75	114.90	114.69	114.72	663.03K
Apr 02, 2026	114.75	114.80	114.66	114.77	1.21M
Apr 01, 2026	114.79	114.94	114.71	114.75	961.07K
Mar 31, 2026	114.80	114.84	114.65	114.82	1.01M
Mar 30, 2026	114.70	114.79	114.60	114.77	1.24M
Mar 27, 2026	114.62	114.82	114.54	114.57	1.65M

Contact Details

Redwood City, MD 20878

United States

https://arcellx.com 240 327 0603

About Company

Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.

Stock Peers

ARGX

-50.35-5.57%

argenx SE$853.40 REGN

5.53+0.90%

Regeneron Pharmaceuticals, Inc.$618.03 UTHR

6.03+1.12%

United Therapeutics Corporation$544.33 MDGL

0.55+0.11%

Madrigal Pharmaceuticals, Inc.$513.43 VRTX

1.63+0.35%

Vertex Pharmaceuticals Incorporated$468.42 KRYS

-3.22-0.94%

Krystal Biotech, Inc.$340.21 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

1.98+0.65%

Praxis Precision Medicines, Inc.$305.37 ALNY

1.77+0.62%

Alnylam Pharmaceuticals, Inc.$288.18 LGND

17.27+6.59%

Ligand Pharmaceuticals Incorporated$279.44

Company Overview

Arcellx, Inc. (NASDAQ:ACLX) closed at $115.07 USD, gaining $0.02 (0.02%) from the previous close of $115.05. The stock is currently trading near its 52-week high $50.85 and $115.13. With a market capitalization of about $6.73 billion, Arcellx, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.25). Key stats such as the average daily volume over the past year has been around 1.45 million shares, trading with heavier-than-usual volume. Headquartered in Redwood City, MD, Arcellx, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rami Elghandour, the company employs approximately 163 people and listed since February 04, 2022. Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases.

Technical Performance

ACLX has shown mixed momentum, gaining 11.25% over the past week and -17.04% over the past quarter, though year-to-date performance is up 10.69%. Short-term trend indicators are mixed aligned (SMA20 47.14%, SMA50 61.04%, SMA200 55.77%). The stock’s 14-day RSI is 83.76 (overbought), while the ATR of 5.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -0.33% below its high and over 137.94% above its low.

Valuation Metrics

Arcellx, Inc. trades at a P/E ratio of -28.27, slightly below the S&P 500 average, with a price-to-sales ratio of 302.09 and a price-to-book ratio of 16.1 reflecting a rich premium to book value. The P/FCF stands at -31.67, also below market averages. Compared to sector medians, Arcellx, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Arcellx, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.28. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Arcellx, Inc. generated EPS of -$3.92 over the past year. Five-year average earnings growth is -31.14%. Wall Street analysts project EPS growth of 4.16% annually over the next five years. The latest quarter delivered EPS of -$1.01. The next quarter is forecast at -$1.05. Next year's EPS is expected at $9.89. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 7 Buy ratings, 11 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $134.00 to $88.00. The high target offers 16.45% upside. The low target suggests -23.52% downside. The mean target is $116.05. This offers 0.85% upside. Arcellx, Inc. earnings surprise history is a mixed track record. The quarter that ended February 26, 2026, missed forecasts by 0.0%. The prior quarter beat by 3.13%. Over the last six quarters, Apple has recorded several small beats. These include -12.62% in November 07, 2024.

Shareholding & Insider Activity

Arcellx, Inc. has 58.51 million shares outstanding. The public float is 42.96 million shares, elevated short interest at 4.18% of float. This equals 1.80 million shares. The short ratio is 1.56 days. Institutional investors hold 119.3% of the float. Insiders own 12.81%. New Enterprise Associates 15, L.P. holds 6.75 million shares, Novo Holdings A/S has 4.02 million shares and SR ONE CAPITAL MANAGEMENT, LLC has 1.66 million shares. Over the past six months, insider transactions show net selling. They sold 130.84 thousand shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Arcellx generated $110.32M in revenue, or $2.30 per share. Gross margin was 98.15%, operating margin -81.47%, and net profit margin -64.08%. Returns are negative, with ROA at -8.57% and ROE at -14.56%.
On valuation metrics, Arcellx trades at a P/E of -28.27, P/S of 302.09 and P/B of 16.10. The current ratio is 4.44 and quick ratio is 4.44. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 3.55 days. Debt-to-equity is 0.24, supported by a cash flow-to-debt ratio of -2.18.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Arcellx posted revenue of $110.32M, down slightly from $0.00 in the prior quarter. Gross profit was $108.28M (margin 98.15%). Operating income was - $89.88M (margin -81.5%). Net income was- $70.69M (EPS - $1.47).
The company ended the quarter with $702.02M in cash and short-term investments, a total debt of $97.63M, and net debt of - $296.96M. Total assets were $825.13M, with equity of $485.38M. Financials further reflected stability, with operating cash flow of $207.57M, free cash flow of $186.15M, and capital expenditures of - $21.43M.

Price Forecast & Outlook

Our AI price prediction model suggests that Arcellx, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 122.92%, reaching $256.51 by August 13, 2026, with a range of $254.65 to $258.84. 1-Year Outlook: Projected gain of 16.64%, with price at $134.22 by May 14, 2027, within a range of $129.61 to $138.86.

Key Takeaways

Arcellx, Inc. (NASDAQ:ACLX) shares are up 10.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcellx, Inc. trading at a premium to the broader market with a P/E of -28.27. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $83.68, suggesting -27.28% downside.

Frequently Asked Questions

What is the current Arcellx, Inc. (ACLX) stock price?

Arcellx, Inc. (NASDAQ: ACLX) stock price is $115.07 in the last trading session. During the trading session, ACLX stock reached the peak price of $115.07 while $115.03 was the lowest point it dropped to. The percentage change in ACLX stock occurred in the recent session was 0.02% while the dollar amount for the price change in ACLX stock was $0.02.

ACLX's industry and sector of operation?

The NASDAQ listed ACLX is part of Biotechnology industry that operates in the broader Healthcare sector. Arcellx, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACLX?

Mr. Narinderjeet Singh M.S.
Chief Technical Officer
Ms. Michelle Lim Gilson
Chief Financial Officer
Mr. Michael Dombeck M.B.A.
Chief Operating Officer
Ms. Kate Aiken
Chief People Officer
Mr. Rami Elghandour
Chairman, Chief Executive Officer & Pres
Mr. David Tice Ph.D.
Chief Scientific Officer
Ms. Maryam Abdul-Kareem J.D., M.S.
Gen. Counsel
Ms. Myesha Lacy
Vice President of Investor Relations
Dr. Christopher R. Heery M.D.
Chief Medical Officer
Mr. Neeraj P. Teotia
Chief Commercial Officer

How ACLX did perform over past 52-week?

ACLX's closing price is 126.29% higher than its 52-week low of $50.85 where as its distance from 52-week high of $115.13 is -0.05%.

How many employees does ACLX have?

Number of ACLX employees currently stands at 163.

Link for ACLX official website?

Official Website of ACLX is: https://arcellx.com

How do I contact ACLX?

ACLX could be contacted at phone 240 327 0603 and can also be accessed through its website. ACLX operates from 25 West Watkins Mill Road, Redwood City, MD 20878, United States.

How many shares of ACLX are traded daily?

ACLX stock volume for the day was 13.19M shares. The average number of ACLX shares traded daily for last 3 months was 1.45M.

What is the market cap of ACLX currently?

The market value of ACLX currently stands at $6.73B with its latest stock price at $115.07 and 58.51M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	163
Beta	0.25
Sales or Revenue	$110.32M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ACLX Company Profile and Key Details

Arcellx

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook